SEC Form 4/A · accession 0001209191-16-141548
Eiger BioPharmaceuticals, Inc. · EIGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Joanne Quan
Officer — Chief Medical Officer
Period of report
Mar 23, 2016
Accepted (ET)
Sep 15, 2016 · 2:58 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001305253
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $15.89 | Mar 23, 2016 | A | 53,452 | A | — | Mar 23, 2026 | Common Stock | 53,452 | 53,452 | D |
Explanation of responses
- F1The option will vest as to 25% of the option shares on March 23, 2017 and vest as to the remaining shares in successive equal monthly installments for the subsequent 36 months subject to Reporting Person's continuous service status as of each such date.
- F2The option grant was approved by Issuer's board of directors on March 22, 2016, subject to stockholder approval of an amendment to the Issuer's 2013 Equity Incentive Plan (the "Plan") under which the option was granted. Issuer's stockholders approved the amendment to the Plan on August 29, 2016.